Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1870MR)

This product GTTS-WQ1870MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1870MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14820MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ3771MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ10873MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ12485MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ15402MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ6208MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ14971MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ11628MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW